Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.37 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866529 | 0.91 | HTR2A (0.44) | KDM4EMCHR1MEN1ALDH1A1KMT2A | |
| SCHEMBL3857968 | 0.87 | HTR2A (0.45) | KDM4EMCHR1MEN1ALDH1A1KMT2A | |
| SCHEMBL3862748 | 0.87 | HTR2A (0.49) | MCHR1MEN1KMT2AQPCT | |
| SCHEMBL3863359 | 0.86 | MCHR1 (0.43) | KDM4EMCHR1MEN1ALDH1A1KMT2A | |
| SCHEMBL3863706 | 0.86 | HTR2A (0.43) | MCHR1ALDH1A1GAATRPV1 | |
| SCHEMBL13683465 | 0.84 | KMT2A (0.49) | KDM4EMCHR1MEN1ALDH1A1LMNA | |
| SCHEMBL3863730 | 0.83 | LMNA (0.45) | KDM4EMEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL3862545 | 0.82 | MCHR1 (0.40) | MCHR1KMT2ATRPV1 | |
| Formic Acid SCHEMBL3863365 | 0.82 | KMT2A (0.47) | KDM4EMCHR1MEN1ALDH1A1KMT2A | |
| SCHEMBL13683437 | 0.81 | MCHR1 (0.51) | KDM4EMCHR1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | KDM4E 1277/4885MCHR1 1/4885MEN1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.